Literature DB >> 16891523

Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using gram-positive organisms.

Thomas R Fritsche1, Robert P Rennie, Beth P Goldstein, Ronald N Jones.   

Abstract

While standardized microdilution testing methodologies and quality control ranges exist for the novel glycolipopeptide dalbavancin, no testing methods have been described that are immediately available for routine use in clinical laboratories. In this study, we found that the dalbavancin Etest (AB BIODISK, Solna, Sweden) procedure demonstrated a high degree of agreement (100% within +/-2 log(2) dilution steps) with the standardized broth microdilution method, validating the use of the Etest as an alternative test for investigational or clinical purposes following regulatory approval.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16891523      PMCID: PMC1594606          DOI: 10.1128/JCM.00640-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  11 in total

1.  Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide.

Authors:  Ronald N Jones; Jennifer M Streit; Thomas R Fritsche
Journal:  Int J Antimicrob Agents       Date:  2004-02       Impact factor: 5.283

Review 2.  Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections.

Authors:  Michael W Ellis; James S Lewis
Journal:  Curr Opin Infect Dis       Date:  2005-12       Impact factor: 4.915

3.  Initial quality control evaluations for susceptibility testing of Dalbavancin (BI397), an investigational glycopeptide with potent gram-positive activity.

Authors:  Tamara R Anderegg; Douglas J Biedenbach; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

4.  Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.

Authors:  Jennifer M Streit; Helio S Sader; Thomas R Fritsche; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2005-12       Impact factor: 2.803

5.  Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).

Authors:  Ronald N Jones; Matthew G Stilwell; Helio S Sader; Thomas R Fritsche; Beth P Goldstein
Journal:  Diagn Microbiol Infect Dis       Date:  2006-01-19       Impact factor: 2.803

6.  Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.

Authors:  Gengrong Lin; Kim Credito; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

7.  Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.

Authors:  Luis E Jauregui; Simon Babazadeh; Elyse Seltzer; Lisa Goldberg; Dainis Krievins; Mark Frederick; David Krause; Igors Satilovs; Zilvinas Endzinas; Jeffrey Breaux; William O'Riordan
Journal:  Clin Infect Dis       Date:  2005-10-06       Impact factor: 9.079

Review 8.  Origin, structure, and activity in vitro and in vivo of dalbavancin.

Authors:  Adriano Malabarba; Beth P Goldstein
Journal:  J Antimicrob Chemother       Date:  2005-03       Impact factor: 5.790

9.  Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods.

Authors:  Shazad Mushtaq; Marina Warner; Alan P Johnson; David M Livermore
Journal:  J Antimicrob Chemother       Date:  2004-08-20       Impact factor: 5.790

10.  Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.

Authors:  Elyse Seltzer; Mary Beth Dorr; Beth P Goldstein; Marc Perry; James A Dowell; Tim Henkel
Journal:  Clin Infect Dis       Date:  2003-10-17       Impact factor: 9.079

View more
  11 in total

1.  Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent.

Authors:  Robert P Rennie; Laura Koeth; Ronald N Jones; Thomas R Fritsche; Cindy C Knapp; Scott B Killian; Beth P Goldstein
Journal:  J Clin Microbiol       Date:  2007-08-01       Impact factor: 5.948

2.  Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States.

Authors:  Douglas J Biedenbach; James E Ross; Thomas R Fritsche; Helio S Sader; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2007-01-10       Impact factor: 5.948

Review 3.  Antimicrobial Susceptibility Testing for Enterococci.

Authors:  Ayesha Khan; William R Miller; Dierdre Axell-House; Jose M Munita; Cesar A Arias
Journal:  J Clin Microbiol       Date:  2022-06-13       Impact factor: 11.677

Review 4.  New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.

Authors:  Truc T Tran; Sara Gomez Villegas; Samuel L Aitken; Susan M Butler-Wu; Alex Soriano; Brian J Werth; Jose M Munita
Journal:  Antimicrob Agents Chemother       Date:  2022-04-27       Impact factor: 5.938

5.  A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically.

Authors:  Laura M Koeth; Jeanna M DiFranco-Fisher; Sandra McCurdy
Journal:  J Vis Exp       Date:  2015-09-09       Impact factor: 1.355

6.  Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.

Authors:  Francis F Arhin; Ingrid Sarmiento; Adam Belley; Geoffrey A McKay; Deborah C Draghi; Parveen Grover; Daniel F Sahm; Thomas R Parr; Gregory Moeck
Journal:  Antimicrob Agents Chemother       Date:  2008-02-25       Impact factor: 5.191

7.  Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014).

Authors:  Ronald N Jones; Jason E Schuchert; Rodrigo E Mendes
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

8.  Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates.

Authors:  Jennifer I Smart; Gordon Ralph Corey; Martin E Stryjewski; Whedy Wang; Steven L Barriere
Journal:  Infect Dis Ther       Date:  2016-10-07

Review 9.  Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review.

Authors:  Luis Buzón-Martín; I Zollner-Schwetz; Selma Tobudic; Emilia Cercenado; Jaime Lora-Tamayo
Journal:  Antibiotics (Basel)       Date:  2021-05-31

10.  History and evolution of antibiotic resistance in coagulase-negative staphylococci: Susceptibility profiles of new anti-staphylococcal agents.

Authors:  Joseph F John; Alexander M Harvin
Journal:  Ther Clin Risk Manag       Date:  2007-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.